GSK Plc (GSK)
57.13
-0.68
(-1.18%)
USD |
NYSE |
Apr 16, 16:00
57.15
+0.02
(+0.04%)
Pre-Market: 20:00
GSK Cash from Investing (Quarterly) : -3.184B for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| AstraZeneca PLC | -1.501B |
| Biodexa Pharmaceuticals Plc | -- |
| Novavax, Inc. | 20.48M |
| BioNTech SE | -3.086B |
| Moderna, Inc. | -48.00M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 2.744B |
| Cash from Financing (Quarterly) | 1.089B |
| Free Cash Flow | 5.712B |
| Free Cash Flow Per Share (Quarterly) | 0.6832 |
| Free Cash Flow to Equity (Quarterly) | 1.457B |
| Free Cash Flow to Firm (Quarterly) | 1.587B |
| Free Cash Flow Yield | 4.87% |